ArticleMolecules (Basel, Switzerland)2026
Humic Acid-Stabilized Biogenic FeS Nanoparticles for Cr(VI) Removal Under Simulated Acidic Mine Drainage Conditions: Optimization and Interfacial Transformation Pathways.
Article in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Acidic mine drainage (AMD) poses a severe global environmental threat due to its high acidity and elevated levels of toxic hexavalent chromium (Cr(VI)), for which biogenic iron sulfide (FeS) nanoparticles have emerged as a promising remediation agent; however, their practical application is hindered by aggregation and oxidative deactivation. This research synthesized biogenic FeS nanoparticles via sulfate-reducing bacteria (SRB) and employed humic acid (HA) as a stabilizing agent to enhance Cr(VI) removal performance in simulated AMD conditions. Single-factor experiments combined with response surface methodology identified the optimal biosynthetic conditions for FeS: yeast extract powder dosage of 2.2 g/L, Fe/S molar ratio of 0.8, and NH
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.